Life sciences companies spend an average of $300,000 to recruit each participant for a Phase III clinical trial. However, despite this investment, 80% of trials fail to meet their initial patient enrolment quotas. Challenges associated with the identification of subjects to participate in a study can cause serious bottlenecks and delay study completion, slowing development, delaying patient access to important therapies, and causing financial losses to sponsors as high as $8 million a day.

To overcome these obstacles as the traditional drug-discovery process continues to grow in cost and complexity, life sciences companies are increasingly looking for ways to achieve sustainable R&D models that lower costs and maximise return on their investments, such as more efficient and effective patient recruitment models. Enter: Clinical Trial Educators (CTEs). CTEs play a relatively new role in the pharmaceutical industry. They are highly qualified nurses, doctors, or other healthcare professionals who support many different aspects of the trial — from training investigators to patient recruitment to consulting on future commercialisation needs. In most cases, CTEs are Registered Nurses and possess credentials that qualify them as peers of a clinical study’s research team, which means they have specialised expertise in the therapeutic area of a study. For example, in a diabetes study, the ideal CTE is a Certified Diabetes Educator with experience in diabetes-related research. In addition, CTEs must demonstrate excellent customer service skills, which is critical to success.

Source: Pharma Horizon

Volume 1 (2) 2017